Cabozantinib is approved in the USA for adults with advanced RCC in both first and subsequent lines of treatment [8], in Europe for adults with treatment-naive advanced RCC with intermediate or poor risk and adults following prior VEGF-targeted therapy [9], and in both the USA and Europe as first-line treatment in combination with nivolumab. Here, VEGFA is linked to renal cell carcinoma.